Puckrin, R., Atenafu, E. G., Claudio, J. O., Chan, S., Gupta, V., Maze, D., McNamara, C., Murphy, T., Shuh, A. C., Yee, K., Sibai, H., Minden, M. D., Wei, C., Stockley, T., Kamel-Reid, S. and Schimmer, A. D. (2021) “Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia”, Haematologica. Pavia, Italy, 106(1), pp. 56-63. doi: 10.3324/haematol.2019.235721.